MarketPeel
Insider Trading Intelligence
Pricing
…
AM

Alison Moore

CDXS
PRESIDENT AND CEO · CODEXIS, INC. · CIK 0001754937
FILING MIX · LIFETIME61%/39%
BUYS
27
SELLS
17
TOTAL VALUE
$5.85M
COMPANIES
3
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
1,439,488
AVG SELL PX
$34.26
TRADE KIND
SHOWING 44 / 44
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Alison Moore, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+60.00%+0.03%-0.05%+0.07%-2.80%—
14d10+70.00%-5.11%+1.71%-6.82%-11.53%—
30d10+80.00%-14.63%+3.57%-18.20%-27.27%—
60d10+80.00%-1.97%+5.14%-7.11%-35.24%—
90d10+70.00%-0.17%+8.14%-8.31%-41.81%—
180d10(1 pending)+77.78%+1.09%+16.55%-15.46%-36.51%—
1y10(2 pending)+87.50%-38.23%+26.20%-64.44%-89.16%—
2y10(2 pending)+100.00%-68.83%+19.41%-88.24%-82.69%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CDXS · 993,000 shares · as of Feb 23, 2026
0248,250496,500744,750993,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 27 buys / 17 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
993,000——993,000Feb 23, 2026Feb 25, 2026 ↗View →
CDXS
CODEXIS, INC.
SALE
President and CEO
3,826$1.31$5.0K250,506Feb 6, 2026Feb 9, 2026 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
85,000——254,332Nov 13, 2025Nov 17, 2025 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
500,000——500,000Nov 13, 2025Nov 17, 2025 ↗View →
CDXS
CODEXIS, INC.
SALE
Chief Technical Officer
6,239$2.51$15.6K169,332Oct 13, 2025Oct 15, 2025 ↗View →
ARTV
ARTIVA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,750——13,750Jun 24, 2025Jun 26, 2025 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
161,250——161,250Feb 5, 2025Feb 7, 2025 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
26,875——175,571Feb 5, 2025Feb 7, 2025 ↗View →
ARTV
ARTIVA BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,500——27,500Oct 21, 2024Oct 22, 2024 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
300,000——300,000Oct 10, 2024Oct 10, 2024 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
50,000——148,696Oct 10, 2024Oct 10, 2024 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
30,120——98,696Jun 11, 2024Jun 13, 2024 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
34,602——68,576Jun 13, 2023Jun 15, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
558,094——672,731Mar 22, 2023Mar 24, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
432,738——432,738Mar 22, 2023Mar 24, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
8,351$5.51$46.0K114,637Mar 14, 2023Mar 16, 2023 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
11,273——33,974Jun 14, 2022Jun 16, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
737,179——737,179Mar 23, 2022Mar 25, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
8,698$7.63$66.4K120,430Mar 15, 2022Mar 17, 2022 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
4,796——22,701Jun 15, 2021Jun 17, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
92,365——92,365Mar 26, 2021Mar 30, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
24,866——127,440Mar 26, 2021Mar 30, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
6,164$38.14$235.1K102,574Mar 15, 2021Mar 17, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
Chief Technical Officer
11,031$2.27$25.0K119,401Oct 13, 2020Oct 13, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
11,031——579,959Oct 13, 2020Oct 13, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
11,031$42.00$463.3K108,370Oct 13, 2020Oct 13, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
24,233——590,990Oct 12, 2020Oct 13, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
24,233$42.00$1.02M108,370Oct 12, 2020Oct 13, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
Chief Technical Officer
24,233$2.27$55.0K132,603Oct 12, 2020Oct 13, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
Chief Technical Officer
30,199$2.27$68.6K147,879Oct 9, 2020Oct 9, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
39,509$41.00$1.62M108,370Oct 9, 2020Oct 9, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
30,199——615,223Oct 9, 2020Oct 9, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
Chief Technical Officer
5,065$2.27$11.5K122,745Oct 8, 2020Oct 9, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
5,065$41.00$207.7K117,680Oct 8, 2020Oct 9, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
5,065——645,422Oct 8, 2020Oct 9, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
44,574$40.00$1.78M117,680Oct 6, 2020Oct 8, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
35,264——650,487Oct 6, 2020Oct 8, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
Chief Technical Officer
35,264$2.27$80.0K161,536Oct 6, 2020Oct 8, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
Chief Technical Officer
32,451$2.27$73.7K126,272Aug 13, 2020Aug 14, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
32,451——685,751Aug 13, 2020Aug 14, 2020 ↗View →
CDXS
CODEXIS, INC.
PURCHASEGRANT
Stock grant
17,905——17,905Jun 16, 2020Jun 18, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
109,600——109,600Mar 18, 2020Mar 20, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,800——93,821Mar 18, 2020Mar 20, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
Chief Technical Officer
3,750$19.19$72.0K63,021Mar 16, 2020Mar 18, 2020 ↗View →
Other insiders · CDXS
Loading peer insiders…
About this filer
CIK 0001754937
ROLE
President and CEO
PRIMARY
CDXS
COMPANIES
3
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001754937DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback